A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Recruiting

Phase 2

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

Sponsor:

Hoffmann-La Roche

Code:

NCT06450639

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 8 - 17

Healthy Volunteers: Not accepted

Interventions

Satralizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information